Laser Recall Dermatitis
Chemotherapy-induced recall dermatitis is a phenomenon whereby the administration of a chemotherapy agent induces an inflammatory reaction at sites injured previously, days, months, or even years earlier.
1 Radiation recall dermatitis, where the inflammatory reaction appears at a previously irradiated site, and reactivation of UV light-induced erythema after methotrexate therapy are the prototypes of recall phenomena. A few cases of chemotherapy recall phenomenon on a site of drug extravasation and on a previously scalded wound have been reported. 1,2 The concept of recall dermatitis is not exclusive for chemotherapy drugs and may also be induced by tuberculostatic drugs, antibiotics, and simvastatin.
3
Report of a Case | A man in his 30s, evaluated for recently diagnosed hairy cell leukemia, developed multiple vesicles over his legs 12 hours after intravenous administration of iopamidol, a nonionic contrast media used for computed tomography (CT) scan. Three days before the onset of lesions, he had undergone his eighth session in a series of diode laser treatments for hair removal, which he tolerated well, showing no immediate injury. The patient denied taking any medication, applying any topical product, or exposing his skin to the sun. Physical examination showed multiple erythematous, vesiculous, well-defined, monomorphic plaques all over the legs and thighs. The lesions appeared only on the laser application areas, with healthy skin around ( Figure) . Skin biopsies revealed a moderate, polymorphous inflammatory infiltrate of lymphocytes, histiocytes, numerous eosinophils, and some neutrophils, with a superficial and deep perivascular and interstitial distribution. The epidermis showed spongiosis and a slight inflammatory exocytosis.
Oral and topical corticosteroid therapy achieved complete resolution of the lesions without pigmentation or scarring.
Discussion | Severe adverse events of laser treatment include hyperpigmentation and hypopigmentation, crusting, blistering, and scarring. The formation of vesicles after laser treatment is a byproduct of thermal epidermal damage. 4 Epidermal necrosis is expected to be present in the histologic findings of the laser burn. Histopathologic features of our case are similar to those observed in drug eruptions. Spongiosis and a dermal inflammatory infiltration composed mainly of lymphocytes with a variable number of eosinophils are present in the skin biopsies of cutaneous reactions to iodinated contrast media. 5 In our patient, the distribution of lesions exclusively on laser application areas suggests that the damage caused by the laser was a decisive factor in the onset of drug reaction to the iopamidol used for CT scan. The pathogenic mechanism of the recall phenomenon is unknown. The onset of the symptoms of recall usually occurs within days to a few weeks after exposure to the precipitating drug, frequently after the first dose, and sometimes during or immediately after intravenous administration.
The marked clinical and histologic differences between the cases induced by different drugs suggest that they are caused by different mechanisms. Any previous insult to the skin would result in increased susceptibility of the local area to the toxic effects of subsequent drug treatments, but probably mechanisms other than a direct toxic effect must be also involved. 1 Some cases may be merely drug reactions confined to areas of previous damage. Although in our case there was no clinically apparent damage, the effect of the previous laser treatment could produce localized edema and vascular changes with increased tissue delivery of drug.
Recall phenomenon has not been associated with laser treatment for hair removal. There is a report of docetaxelinduced recall dermatitis on previous Nd:YAG laser treatment sites.
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In conclusion, the temporal relationship between contrast media administration and the appearance of the cutaneous lesions and distribution exclusively on laser treatment sites suggest that this case would correspond to recall phenomenon.
Figure. Multiple Vesiculous Plaques Over the Laser Application Areas
The skin between the laser spots and the untreated area on the knees is preserved.
Letters

Neutrophilic Lobular Panniculitis as an Expression of a Widened Spectrum of Familial Mediterranean Fever
Familial Mediterranean fever (FMF) is considered to be an autosomal recessive disease, though it is controversial.
1-3
The marenostrin-encoding fever gene (MEFV) is responsible for FMF. The most frequent mutation is M694V, which represents a genetic risk factor for development of amyloidosis 1 and more severe disease. The classic clinical picture consists of generally short recurrent febrile episodes, serositis, and erysipelas-like erythema (ELE). Colchicine is the treatment of choice for prevention of the attacks and AA amyloidosis. With isolation of the MEFV gene in 1997, incomplete or "atypical" forms of FMF have been reported and are considered by some authors an expanded spectrum of the disease.
2
Report of a Case | An infant without relevant medical or family history presented with tender, erythematous, contusiform, warm nodules of irregular shape on the limbs (Figure 1 ) and face. The lesions healed as grayish macules without lipoatrophy. Coinciding with the skin lesions, she had periodic febrile episodes (temperature up to 40ºC) lasting from 3 days to several weeks, malaise, and increased levels of acute-phase reactants. No other signs or symptoms were observed.
Three skin biopsy specimens were obtained. Histologic examination revealed a predominantly lobular neutrophilic panniculitis without evidence of necrosis, vasculitis, crystals, destruction of adipocytes, or infiltration at eccrine structures. Periodic acid-Schiff, Grocott, and EBER stainings were negative. Lipophagic histiocytes and giant cells were present in older lesions (Figure 2) . Our differential diagnosis included pancreatic panniculitis, α 1 -antitrypsin deficiency, infective panniculitis, and panniculitis associated with rheumatic disease. We also considered subcutaneous Sweet syndrome, idiopathic infantile febrile panniculitis, and autoinflammatory disease.
The patients clinical course was complicated, with over a year of recurrent episodes, malaise, corticosteroid dependence, and no response to methotrexate, 2.5 mg/wk, or nonsteroidal anti-inflammatory drugs. All laboratory findings were negative but for the genetic evaluation for autoinflammatory syndromes that evidenced an M694V single mutation in the MEFV gene. Colchicine treatment was started at 0.5 mg/d. After 2 weeks of treatment, the patient did not present new episodes. This response persisted after 13 months of treatment. The patient satisfied major and minor Tel Hashomer criteria corresponding to a "probable" diagnosis.
Discussion | In the multiple articles that describe clinical and genetic features of FMF, 10% to 40% heterozygous mutations were detected. 1, 3 In fact, there is a series of 94 patients 3 carrying a single mutated allele and sharing clinical features with our case: a younger age of onset, longer febrile periods, and a majority of skin eruptions that were not typical ELE. The experts highlight the clinical and therapeutic importance of these single mutations and propose a therapeutic trial with colchicine to support FMF diagnosis. 1,2 Finally, some authors warn about an expanded spectrum of FMF with new recurrent clinical manifestations that should be considered in cases with rare mutations and mutations in heterozygosis.
The genetic explanation for developing symptoms while carrying a single mutated allele lies in several hypotheses 3 : a dominant inherence with incomplete penetrance under certain environmental backgrounds, oligogenism, difficulties in the detection of rare mutations, and pseudodominance phenomenon. 
